Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis.

In 30 seconds

This systematic review and meta-analysis pooled adverse-event data from six randomized controlled trials involving 1,736 patients with multiple myeloma treated with elotuzumab-containing regimens or control therapies. Elotuzumab was associated with lower neutropenia risk (RR = 0.86, 95% CI: 0.76-0.98), but higher risks of pneumonia, diarrhea, pyrexia and infections. For grade 3-4 events, increased risks included lymphopenia, diarrhea, pneumonia, cataracts and infections. The authors characterized the overall safety profile as acceptable while noting a distinct pattern of adverse events and cautioning that treatment duration and corticosteroid use may influence some findings.

Key findings

• Elotuzumab-containing regimens reduced neutropenia incidence (RR = 0.86, 95% CI: 0.76-0.98).
• Risks of pneumonia (RR = 1.30, 95% CI: 1.07-1.59), diarrhea (RR = 1.16, 95% CI: 1.05-1.30), pyrexia (RR = 1.47, 95% CI: 1.10-1.96) and infections (RR = 1.09, 95% CI: 1.03-1.15) were higher.
• Grade 3-4 lymphopenia was more frequent with elotuzumab (RR = 1.86, 95% CI: 1.31-2.64, p = 0.0005, I2 = 9%).
• Grade 3-4 risks were also higher for diarrhea, pneumonia, cataracts and infections.

Why it matters

The pooled trial evidence suggests that elotuzumab’s safety profile involves both a lower risk of neutropenia and increased risks of selected infectious, gastrointestinal and other adverse events. This helps frame safety monitoring around the specific events identified, while distinguishing overall adverse-event findings from severe events. The authors also caution that longer treatment and corticosteroid use may affect interpretation of outcomes such as hyperglycemia and cataracts.

What to keep in mind

The analysis pooled only six randomized trials; the abstract notes that longer treatment and corticosteroid use may influence some adverse-event findings.